Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Verrica Pharmaceuticals, Inc.

https://verrica.com/

Latest From Verrica Pharmaceuticals, Inc.

The Quality Lowdown: Wishing Wished-For FDA Re-Inspections Had Gone Better?

As the COVID-19 pandemic wore on, industry clamored for the US FDA to re-inspect troubled drug manufacturing plants remotely if need be to clear them for new approvals. Now FDA investigators are out in force and early returns from Sun, Aurobindo, Lupin and Sterling suggest these re-inspections will be as tough as ever.

Manufacturing Quality

Keeping Track: US FDA Clears Vtama, But Not Bimekizumab Or Ycanth; Tibsovo Takes RTOR To Frontline AML Setting

The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker.

US FDA Performance Tracker Approvals

Four Major Approval Decisions To Watch Out For In Q2

Having looked at four prominent drug candidates which are expecting important top-line data this quarter, with the help of Biomedtracker's Q2 Outlook Report, we take a look at four other assets that could soon break into the US market, from infectious diseases to diabetes.

Drug Review Companies

Bad Times For Breakthrough Drugs Targeting Chemo Complications; Submissions From BMS, Merck

The latest news about applications under FDA review, from the Pink Sheet’s US FDA Performance Tracker

US FDA Performance Tracker Complete Response Letters
See All

Company Information

  • Industry
  • Pharmaceuticals
UsernamePublicRestriction

Register